Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
Expanding Indications: Beyond Obesity and Diabetes The GLP-1 drug pipeline in 2026 reaches well beyond weight management and glycaemic control
Metformin (off-label for weight management) Metformin is the most widely prescribed diabetes medication in the world, and while it is not FDA-approved for weight loss, it consistently produces modest weight reduction of 2-5% in clinical studies
If you are considering GLP-1 medication or already taking semaglutide and want guidance on optimizing your exercise routine, we invite you to schedule a consultation
JAMA 2025;333:1062-73.ArticlePubMedPMC 136
Treatment should be about improving health and quality of life, not about conforming to societal beauty standards or reinforcing harmful weight stigma
A., Lee, W., Fahim, S
US$ 23.26
US$ 27.08
US$ 23.75
US$ 23.01
US$ 28.32
